astrazeneca glp 1 drug AstraZeneca's oral obesity Elecoglipron has advanced to Phase III clinical trials after delivering promising Phase II results, with patients achieving up to 11.8% weight loss over 36 weeks. This milestone highlights Encouraging trial results for AstraZeneca's

The current data showing that GLP-1 drugs may lower cancer risk are from retrospective studies , which means researchers looked back at medical records of patients who were taking GLP-1s for other reasons and tracked who developed cancer

Biobank: 1 U24 OD023121

Book your IV Drip appointment or browse our IV Drip Menu

Getting the Lipo-B (MIC) Injection Disclaimer: These products have not been evaluated by the Food and Drug Administration

By placing an order, you confirm that you understand the intended use of these products

Our 1200mg Glutathione preparation offers twice the concentration of our standard formulation, designed for practitioners running higher-dose antioxidant protocols or who prefer to dilute to their required strength in-clinic